Compare MPB & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MPB | IVA |
|---|---|---|
| Founded | 1868 | 2011 |
| Country | United States | France |
| Employees | N/A | 77 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 827.5M | 883.8M |
| IPO Year | 1996 | N/A |
| Metric | MPB | IVA |
|---|---|---|
| Price | $38.45 | $4.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $37.00 | $16.20 |
| AVG Volume (30 Days) | 160.2K | ★ 1.3M |
| Earning Date | 04-21-2026 | 03-30-2026 |
| Dividend Yield | ★ 2.66% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $30.95 | N/A |
| Revenue Next Year | $9.45 | $751.20 |
| P/E Ratio | $104.86 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.56 | $2.94 |
| 52 Week High | $38.32 | $7.98 |
| Indicator | MPB | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 72.30 | 59.78 |
| Support Level | $30.82 | $4.48 |
| Resistance Level | N/A | $4.70 |
| Average True Range (ATR) | 0.94 | 0.24 |
| MACD | 0.29 | 0.04 |
| Stochastic Oscillator | 86.87 | 84.47 |
Mid Penn Bancorp Inc is a financial holding company, providing various banking and financial products and services through its subsidiaries. These products and services mainly include consumer banking products, including secure checking and savings accounts, mobile banking, agricultural loans, construction financing, mortgages, home equity loans and lines of credit, credit cards, and more. Additionally, the Group offers trust services, insurance products, wealth management, and private banking services. The Group caters to individuals, partnerships, non-profit organizations, and corporations through its retail banking offices located throughout Pennsylvania, with a minor portion in New Jersey.
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.